WFH/LinkedIn
Feb 28, 2026, 14:48
WFH Acknowledges BioMarin’s Decision to Discontinue ROCTAVIAN
World Federation of Hemophilia (WFH) shared a post on LinkedIn:
“WFH Statement: the WFH acknowledges BioMarin’s decision to discontinue ROCTAVIAN and the importance of this development for the hemophilia community.
We urge BioMarin and other gene therapy developers to continue rigorous long-term safety monitoring of all discontinued products, and to preserve and share relevant clinical data that can inform ongoing scientific understanding and support patient safety.
For the full WFH position and our emphasis on preserving data in the WFH Gene Therapy Registry, please read our complete statement here.”
Other articles about World Federation of Hemophilia on Hemostasis Today.
-
Feb 28, 2026, 14:43Fabrice Cognasse: Honored to Contribute to New Reference Work on Platelets in Disease
-
Feb 28, 2026, 14:36Shadi Tabibian: Global Trends in Prenatal Diagnosis of Hemophilia A and B Over Two Decades
-
Feb 28, 2026, 14:14Omar Adwan։ ESR in Inflammation and Disease Assessment
-
Feb 28, 2026, 12:56Sinju Thomas: Presenting Gene Therapy Collection Challenges at the Apheresis Hub Conference 2026
-
Feb 28, 2026, 12:54Mahesan Subramaniam: Supporting Circulation and Managing Cholesterol Protects Heart and Brain
-
Feb 28, 2026, 12:09Gonzalo Montero Martin: A Breakthrough in HLA Nomenclature for Transplant Evaluation
-
Feb 28, 2026, 11:47Abdul Mannan: Paradox of Bleeding and Clotting in Uremic Coagulopathy
-
Feb 28, 2026, 11:40Jim Hoffman: Could Extracorporeal Removal of NETs Become a ‘Holy Grail’ Therapy Across Multiple Diseases?
-
Feb 27, 2026, 18:30Sanjeev Saksena: From Isolated Case Reports to Clinical Evidence for Post-Ablation Myocardial Ischemia